IQVIA, the world’s leading provider of clinical research services, commercial insights and healthcare intelligence, is working with NVIDIA to build custom foundation models and agentic AI workflows that can accelerate research, clinical development and access to new treatments.
AI applications trained on the organization’s vast healthcare-specific information and guided by its deep domain expertise will help the industry boost the efficiency of clinical trials and optimize planning for the launch of therapies and medical devices — ultimately improving patient outcomes.
Operating in over 100 countries, IQVIA has built the largest global healthcare network and is uniquely connected to the ecosystem with the most comprehensive and granular set of information, analytics and technologies in the industry.
Announced today at the J.P. Morgan Conference in San Francisco, IQVIA’s collection of models, AI agents and reference workflows will be developed with the NVIDIA AI Foundry platform for building custom models, allowing IQVIA’s thousands of pharmaceutical, biotech and medical device customers to benefit from NVIDIA’s agentic AI capabilities and IQVIA’s technologies, life sciences information and expertise.
Enabling Industry Applications in Clinical Trials
The healthcare and life sciences industry generates more information than any other industry in the world, making up 30% of the world’s data volume.
IQVIA plans to use its unparalleled information assets, analytics and domain expertise — known as IQVIA Connected Intelligence — with the NVIDIA AI Foundry service to build language and multimodal foundational models that will power a collection of customized IQVIA AI agents.
These agents are anticipated to be available in predefined workflows, or blueprints, that would accomplish a specific task. This partnership aims to accelerate the innovation cycle of IQVIA Healthcare-grade AI. IQVIA has been leading in the responsible use of AI, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance and patient safety. IQVIA Healthcare-grade AI represents the company’s commitment to these principles.
One key opportunity area is in clinical development, when clinical trials are conducted for new drugs. The overall process takes about 11 years, on average, and each trial has a multitude of workflows that could be supported by AI agents. For example, just starting a clinical trial involves site selection, participant recruitment, regulatory submissions and tight communication between study sites and their sponsors.
NVIDIA AI Foundry Streamlines Custom Model Development
To streamline the development of these AI agents, IQVIA is using tools within NVIDIA AI Foundry and the NVIDIA AI Enterprise software platform, including NVIDIA NIM microservices, especially the Llama Nemotron and Cosmos Nemotron model families; NVIDIA AI Blueprint reference workflows; the NVIDIA NeMo platform for developing custom generative AI; and dedicated capacity on NVIDIA DGX Cloud.
The NVIDIA AI Blueprint for multimodal PDF data extraction can help IQVIA unlock the immense amount of healthcare text, graphs, charts and tables stored in PDF files, bringing previously inaccessible information to train AI models and agents for domain-specific and even customer-specific applications. NVIDIA RAPIDS data science libraries then accelerate the construction of knowledge graphs.
Additional AI agents could automate complex, time-consuming tasks, like document generation and patient recruitment, allowing healthcare professionals to focus on strategic decision-making and human interaction.
Learn more about NVIDIA technologies and their impact on healthcare and life sciences.